US, EU filings imminent for Novartis’ MS therapy siponimod
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.
Read More
Tag: S1P receptor
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
